Company intelligence / Profile preview
Neurosterix
New York*, NY, USAneurosterix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neurosterix is a newly launched biopharmaceutical company focused on developing allosteric modulators for neurological disorders. Its lead program is an M4 positive allosteric modulator for schizophrenia, currently in preclinical development and advancing toward clinical studies. The company leverages a proprietary high-throughput platform acquired from Addex Therapeutics to identify highly selective small molecule drugs with improved efficacy and safety profiles
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (specifically allosteric modulators)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Neurosterix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurosterix.